SAILIFE
Sai Life share price & financials
- Price
- ₹1,216.4
- Market cap
- ₹31.1k Cr
- Sector
- Healthcare
- Calls analysed
- 6
Sai Life Q1 FY27
What went well
- Revenue of INR 553 crores, up 12% YoY, demonstrating strong growth.
- CRO business showed robust growth of 26% YoY, contributing 40% to total revenue.
- Secured the prestigious EcoVadis Platinum rating 2026, placing the company among the top 1% globally for sustainability.
What to watch
- CDMO growth was relatively slower at 6% YoY this quarter.
- Management was evasive regarding the strategy for monoclonal antibodies (mAb) space.
What Sai Life does
Sai Life Sciences is a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO) focused on small-molecule new chemical entities, partnering with global pharmaceutical and biotech companies from early discovery through commercial-scale manufacturing. It operates two reported business lines: Discovery Services (CRO), covering medicinal and synthetic chemistry, biology, DMPK and toxicology; and CMC/Manufacturing Services (CDMO), covering process R&D, analytical development and GMP-compliant manufacturing including complex and HPAPI chemistry. Discovery and process R&D are carried out at an integrated R&D campus in Hyderabad and satellite labs in Manchester (UK) and Greater Boston (US), while commercial-scale manufacturing is based at facilities in Hyderabad and Bidar, India. It earns revenue through outsourced discovery, development and manufacturing contracts with pharmaceutical innovators, including many of the world's largest pharma companies.
Segments
- CDMO
- CRO
- Installed manufacturing capacity
- 700 KL
- Production trains
- 80
- Global R&D and manufacturing locations
- 4 (Hyderabad & Bidar, India; Manchester, UK; Greater Boston, US)
- Total employees
- 3,800+
- Active global clients
- 300+, including 19 of the top 25 global pharma companies
- Active commercial (NCE) molecules
- 34
Guidance record · Q1 FY27
what the last two calls moved 13 tracked 1 delivered 3 missed 9 open- EBITDA Margin delivered said Q3 FY25 Promised: 28-30% steady state in the next 2-3 years Q1 FY27: Management reiterated confidence in sustaining the 28-30% EBITDA range.
- Total Capex FY26 went quiet said Q4 FY25 Promised: Close to INR 700 crores for FY26 Q1 FY27: FY26 has concluded, but management did not provide a final figure for the full-year capex spend. Focus shifted to FY27 guidance.
- Manufacturing Capacity Addition diluted said Q3 FY25 Promised: 100 KL in Q1 FY26 Q1 FY27: Promise relates to a past quarter, status remains unchanged.
All 13 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 13.3%, net profit up 22.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 382 | 429 | 567 | 483 | 527 +38% | 549 +28% | 594 +5% | 547 +13% |
| EBITDA | 101 | 111 | 154 | 113 | 140 +39% | 179 +61% | 168 +9% | 140 +24% |
| Net profit | 44 | 51 | 90 | 58 | 83 +89% | 98 +92% | 103 +14% | 71 +22% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +83.9% 1Y
1Y: ₹861.7 on 10 Sept 2025 → ₹1,585. High ₹1,675.4 (9 Sept 2026), low ₹795 (23 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- −3.4%
- 7 Aug
- Q3 FY26
- +4.8%
- 6 Feb
- Q2 FY26
- −5.1%
- 7 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue fell 80.2% a year over 2 years, FY24 to FY26. Operating margin widened to 27.9%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹54.9k Cr | ₹1.6k Cr | ₹2.2k Cr |
| Operating profit | ₹5.7k Cr | ₹391 Cr | ₹600 Cr |
| Operating margin | 10.5% | 23.8% | 27.9% |
| Interest | ₹1.3k Cr | ₹70 Cr | ₹33 Cr |
| Depreciation | ₹2.7k Cr | ₹126 Cr | ₹152 Cr |
| Net profit | ₹1.6k Cr | ₹174 Cr | ₹342 Cr |
| Net margin | 3.0% | 10.6% | 15.9% |
| Cash from operations | ₹251 Cr | ₹330 Cr | ₹495 Cr |
| Free cash flow | ₹72 Cr | ₹-33 Cr | ₹-94 Cr |
| ROCE | 11.0% | 14.0% | 19.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹4.1k Cr | ₹21 Cr |
| Reserves | ₹850 Cr | ₹873 Cr | ₹895 Cr | ₹993 Cr | ₹54.1k Cr | ₹2.5k Cr |
| Borrowings | ₹637 Cr | ₹752 Cr | ₹869 Cr | ₹868 Cr | ₹33.7k Cr | ₹223 Cr |
| Other liabilities | ₹312 Cr | ₹464 Cr | ₹349 Cr | ₹361 Cr | ₹42.2k Cr | ₹872 Cr |
| Total liabilities | ₹1.8k Cr | ₹2.1k Cr | ₹2.1k Cr | ₹2.2k Cr | ₹134.2k Cr | ₹3.6k Cr |
| Fixed assets | ₹659 Cr | ₹701 Cr | ₹923 Cr | ₹1.1k Cr | ₹72.4k Cr | ₹1.7k Cr |
| Capital work in progress | ₹236 Cr | ₹345 Cr | ₹151 Cr | ₹107 Cr | ₹8.8k Cr | ₹270 Cr |
| Investments | ₹63 Cr | ₹64 Cr | ₹80 Cr | ₹80 Cr | ₹4.1k Cr | ₹163 Cr |
| Other assets | ₹858 Cr | ₹996 Cr | ₹977 Cr | ₹979 Cr | ₹48.8k Cr | ₹1.5k Cr |
| Total assets | ₹1.8k Cr | ₹2.1k Cr | ₹2.1k Cr | ₹2.2k Cr | ₹134.2k Cr | ₹3.6k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public trimmed −15.53 pp while DIIs added +11.07 pp. The shareholder count shrank 1% to 1,25,096.
- Promoters
- 34.5%
- FIIs
- 19.6%
- DIIs
- 32.7%
- Public
- 13.1%
Since Jun 2025
- Public −15.53 pp
- DIIs +11.07 pp
- FIIs +5.08 pp
How it drifted, 7 quarters
Over this window the public fell from 41.1% to 13.1% — −28.0 pp.
Ownership split by quarter, oldest first. Dec '24: Promoters 35.2%, FIIs 11.7%, DIIs 11.9%, Public 41.1%.Mar '25: Promoters 35.2%, FIIs 12.4%, DIIs 13.3%, Public 39.2%.Jun '25: Promoters 35.1%, FIIs 14.6%, DIIs 21.6%, Public 28.6%.Sep '25: Promoters 35.0%, FIIs 22.5%, DIIs 29.9%, Public 12.7%.Dec '25: Promoters 34.7%, FIIs 21.4%, DIIs 31.4%, Public 12.5%.Mar '26: Promoters 34.6%, FIIs 21.2%, DIIs 31.5%, Public 12.7%.Jun '26: Promoters 34.5%, FIIs 19.6%, DIIs 32.7%, Public 13.1%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Invesco India Manufacturing Fund Mutual fund newly disclosed 7.44% held
- Axis Max Life Insurance Limited A/C Uegfh - High G Insurer newly disclosed 1.54% held
- Mirae Asset Small Cap Fund Mutual fund newly disclosed 1.16% held
- DSP Healthcare Fund Mutual fund newly disclosed 1.06% held
- Aditya Birla Sun Life Trustee Private Limited A/C Mutual fund +0.51 pp 2.76% held
- Nippon Life India Trustee Ltd A/C Nippon India Mnc Mutual fund +0.50 pp 6.66% held
The same filing shows 3 holders trimming and 5 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Sai Life above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| MYTREYI KANUMURI Partner of Marigold Partners (Partnership Firm) | 10.45% | unchanged |
| Invesco India Manufacturing Fund Mutual fund | 7.44% | newly disclosed |
| RANGA RAJU KANUMURI Partner of Sunflower Partners (Partnership Firm) | 7.35% | unchanged |
| Nippon Life India Trustee Ltd A/C Nippon India Mnc Mutual fund | 6.66% | +0.50 pp |
| Gokaraju Subba Raju | 4.54% | unchanged |
| MYTREYI KANUMURI Partner of Tulip Partners (Partnership Firm) | 4.37% | unchanged |
| RANGA RAJU KANUMURI Partner of Lily Partners (Partnership Firm) | 3.25% | unchanged |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual F Mutual fund | 2.90% | unchanged |
| Aditya Birla Sun Life Trustee Private Limited A/C Mutual fund | 2.76% | +0.51 pp |
| Smallcap World Fund, Inc Global fund house | 2.57% | unchanged |
| Sai Quest Syn Private Limited | 2.16% | unchanged |
| HSBC Mutual Fund - HSBC Aggressive Hybrid Fund Mutual fund | 1.86% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in SAILIFE
Filings to Aug 2026
0 new, 7 added, 1 trimmed, 0 sold out — net +4.09 L shares (+2.4%).
- Held by funds
- ₹2.5k Cr
- 18 schemes
- Biggest holder
- Nippon India Small Cap Fund
- ₹958 Cr · 1.2% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Small Cap Fund Nippon India Mutual Fund | ₹958 Cr | held | Dec '24 |
| Nippon India Multi Cap Fund Nippon India Mutual Fund | ₹579 Cr | +4.00 L | Dec '24 |
| Nippon India Pharma Fund Nippon India Mutual Fund | ₹373 Cr | held | Dec '24 |
| SBI Healthcare Opportunities Fund SBI Mutual Fund | ₹146 Cr | held | Jan '26 |
| HDFC Multi Cap Fund HDFC Mutual Fund | ₹90 Cr | held | Dec '24 |
| Nippon India Balanced Advantage Fund Nippon India Mutual Fund | ₹81 Cr | held | Jul '25 |
| HDFC Large and Mid Cap Fund HDFC Mutual Fund | ₹57 Cr | held | Dec '24 |
| HDFC Pharma and Healthcare Fund HDFC Mutual Fund | ₹48 Cr | held | Dec '24 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
7 added, 1 trimmed — net +4.09 L shares (+2.4%)
- Funds are sitting on
- +47%
- vs est. average cost
- Held by funds
- ₹2.5k Cr
- 18 schemes · ≈ 6.7% of the company
- Biggest holder
- Nippon India Small Cap Fund
- ₹958 Cr · 1.2% of that fund
Shares held by these funds +243%
Dec '24 1.68 cr shares Jul '26
All earnings calls (6)
Read the Q1 FY27 call →Learn to analyse Sai Life
Guides on how to read this kind of business and the numbers that matter.